Company: DNLI
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001714899-25-000066
Chunk: 186

Company: Denali Therapeutics Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 8
Chunk 186
---
,377 2,648 10,918 Contract liabilities— — (31,313)Related party contract liability— (290,532)(3,149)Other non-current liabilities— (379)— Net cash used in operating activities(347,694)(357,991)(244,716)Investing activitiesMaturities of marketable securities1,157,120 2,075,947 991,486 Purchases of marketable securities(1,229,964)(1,813,700)(1,115,040)Purchases of property and equipment(15,912)(12,939)(17,833)Net cash provided by (used in) investing activities(88,756)249,308 (141,387)Financing activitiesProceeds from issuance of common stock and pre-funded warrants, net of issuance costs of $480499,253 — — Proceeds from public offering of common stock, net of issuance costs— — 296,215 Proceeds from exercise of awards under equity incentive plans17,389 17,820 14,455 Payments for finance lease right-of-use asset(32,338)— — Net cash provided by financing activities484,304 17,820 310,670 Net increase (decrease) in cash, cash equivalents and restricted cash47,854 (90,863)(75,433)Cash, cash equivalents and restricted cash at beginning of year128,681 219,544 294,977 Cash, cash equivalents and restricted cash at end of year$176,535 $128,681 $219,544 Supplemental disclosures of cash flow informationEquity consideration received in the divestiture of small molecule programs (Note 13)$15,000 $— $— Increase in right-of-use asset due to lessor assets$7,051 $— $— Right-of-use asset obtained in exchange for new finance lease liabilities$9,358 $— $— Property and equipment purchases accrued but not yet paid$1,192 $553 $1,464 Cash paid for finance lease interest$302 $— $— Issuance costs incurred but not yet paid$— $— $224 Cash paid during the year for income taxes$— $3 $47 

See accompanying notes to consolidated financial statements.

140